{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.2","upperLimit":"58.9","value":"51.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"}],"units":"Participants"}],"description":"The primary endpoint was the percentage of participants in major molecular response (MMR) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment were considered as non-responders.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who completed the nilotinib treatment consolidation (NTCS) phase and maintained major molecular response entered the treatment-free remission (TFR) phase. During the TFR phase, nilotinib treatment was discontinued and participants were monitored regularly for molecular response.","id":"OG000","title":"TFR Phase"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) included all participants who completed 52 weeks of nilotinib treatment in the NTCS phase and subsequently entered the TFR phase at the corresponding response category.","reportingStatus":"POSTED","timeFrame":"48 weeks in TFR","title":"Percentage of Participants in Major Molecular Response at 48 Weeks After Start of Treatment-Free Remission (TFR) Phase","type":"PRIMARY","unitOfMeasure":"percentage of participants"}